European Commission refocuses efforts to emphasise bio-economy
This article was originally published in Clinica
In a mid-term review of the Strategy on Life Sciences and Biotechnology 2002-10, presented by European Commission president Barroso and commissioners Verheugen and Potocnik, a refocus has been proposed to promote a competitive and sustainable European knowledge-based bio-economy. With the recognition that emerging medical technologies are among the sectors that need to benefit from the strategy, the European Commission wants to put a special focus on innovation, research, market development and the debate with society on ethical issues in the field of biotechnology. The Commission recognises that despite many successful European biotech start-ups, EU biotech companies tend to grow slowly and depend on external finance for their research and development.
You may also be interested in...
Celltrion has announced plans to add a third biopharmaceutical facility and a new global biotechnology research center at the Korean firm’s existing site in Songdo, Incheon, as the firm also revealed record third-quarter financial results.
An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies.
Australian patients with phototoxicity due to the rare condition EPP will now have their first treatment option – provided the drug's developer, Clinuvel, secures reimbursement under the Pharmaceutical Benefits Scheme.